Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Total Non-Current Liabilities (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $4.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 2.62% year-over-year to $4.6 million, compared with a TTM value of $4.6 million through Sep 2025, down 2.62%, and an annual FY2024 reading of $5.6 million, down 14.83% over the prior year.
  • Total Non-Current Liabilities was $4.6 million for Q3 2025 at Lisata Therapeutics, up from $4.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $6.6 million in Q4 2023 and bottomed at $3.8 million in Q1 2025.
  • Average Total Non-Current Liabilities over 3 years is $4.9 million, with a median of $4.7 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities rose 2.32% in 2024, then fell 28.61% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $6.6 million in 2023, then fell by 14.83% to $5.6 million in 2024, then dropped by 18.62% to $4.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for LSTA at $4.6 million in Q3 2025, $4.3 million in Q2 2025, and $3.8 million in Q1 2025.